文献速递糖尿病

糖尿病患者因COVID-19住院时的炎症、高血糖与不良结局

Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19.
PubMed 文献 · Diabetes Care · 2022-01-01

国际炎症研究(ISIC)多中心观察性研究纳入2044例COVID-19住院患者,其中糖尿病患者686例(33.5%)。糖尿病患者主要复合结局累积发生率高于无糖尿病患者(37.8% vs 28.6%),校正可溶性尿激酶纤溶酶原激活物受体(suPAR)水平后糖尿病与主要结局的关联消失(校正比值比1.23 [95%CI 0.78, 1.37]),中介分析估计suPAR介导了84.2%的效应;高血糖和较高胰岛素剂量是主要结局的独立预测因素,效应量不受suPAR校正影响。

要点

  • 糖尿病患者主要复合结局累积发生率37.8%,无糖尿病患者28.6%。
  • 校正suPAR后糖尿病与主要结局关联消失,中介比例估计84.2%。
  • 高血糖和较高胰岛素剂量是主要结局独立预测因素,不受suPAR影响。

核心结论

  • 研究结果提示糖尿病与COVID-19结局的关联在很大程度上由以suPAR水平评估的高炎症反应介导,而高血糖的影响独立于炎症。

研究设计与样本

  • 国际炎症研究(ISIC)为多中心观察性研究,纳入2044例COVID-19住院患者,其中糖尿病患者686例(33.5%),平均年龄60岁,男性58.2%。

主要发现

  • 糖尿病患者主要复合结局(院内死亡、需机械通气、需肾脏替代治疗)累积发生率为37.8%,无糖尿病患者为28.6%。
  • 糖尿病患者炎症生物标志物水平高于无糖尿病患者,多变量分析中糖尿病仅与较高的suPAR水平相关。
  • 校正suPAR水平后糖尿病与主要结局的关联消失(校正比值比1.23 [95%CI 0.78, 1.37])。
  • 中介分析估计suPAR介导了糖尿病对主要结局效应的84.2%。
  • 高血糖和较高胰岛素剂量是主要结局的独立预测因素,校正suPAR水平后效应量不变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Diabetes mellitus (DM) is a major risk factor for severe coronavirus disease 2019 (COVID-19) for reasons that are unclear. RESEARCH DESIGN AND METHODS: We leveraged the International Study of Inflammation in COVID-19 (ISIC), a multicenter observational study of 2,044 patients hospitalized with COVID-19, to characterize the impact of DM on in-hospital outcomes and assess the contribution of inflammation and hyperglycemia to the risk attributed to DM. We measured biomarkers of inflammation collected at hospital admission and collected glucose levels and insulin data throughout hospitalization. The primary outcome was the composite of in-hospital death, need for mechanical ventilation, and need for renal replacement therapy. RESULTS: Among participants (mean age 60 years, 58.2% males), those with DM (n = 686, 33.5%) had a significantly higher cumulative incidence of the primary outcome (37.8% vs. 28.6%) and higher levels of inflammatory biomarkers than those without DM. Among biomarkers, DM was only associated with higher soluble urokinase plasminogen activator receptor (suPAR) levels in multivariable analysis. Adjusting for suPAR levels abrogated the association between DM and the primary outcome (adjusted odds ratio 1.23 [95% CI 0.78, 1.37]). In mediation analysis, we estimated the proportion of the effect of DM on the primary outcome mediated by suPAR at 84.2%. Hyperglycemia and higher insulin doses were independent predictors of the primary outcome, with effect sizes unaffected by adjusting for suPAR levels. CONCLUSIONS: Our findings suggest that the association between DM and outcomes in COVID-19 is largely mediated by hyperinflammation as assessed by suPAR levels, while the impact of hyperglycemia is independent of inflammation.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Vasbinder A, Anderson E, Shadid H, et al. Inflammation, Hyperglycemia, and Adverse Outcomes in Individuals With Diabetes Mellitus Hospitalized for COVID-19. Diabetes Care. 2022. PMID: 35045184. doi:10.2337/dc21-2102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。